Blatt has more than 29 years of drug research and development experience with a specific focus on biology of the immune system, infectious diseases, antiviral therapies, and relevant therapeutic interventions.
Until recently, he was the global head of infectious diseases and vaccines at Johnson and Johnson. He founded Alios BioPharma, which developed therapies for viral diseases, including respiratory syncytial virus and hepatitis C.
Prior to Alios, he was chief scientific officer of InterMune. He also held successive positions as vice president of research of Sirna/Ribozyme Therapeutics, vice president of product development at National Genetics Institute, and product development team leader, interferons at Amgen.
Blatt achieved a Ph.D. in public health administration from the University of La Verne and completed his MBA from California State University, Northridge.
Privately held Meissa Vaccines is developing vaccines to prevent viral respiratory infections. It is focused on the advancement of vaccines for respiratory syncytial virus and rhinovirus. The company is also developing vaccines for parainfluenza virus and human metapneumovirus.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer